ClinicalTrials.gg
CompletedNCT00277498Updated Feb 18, 2021

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

A Phase 3 interventional study of Xalacom and Xalatan in Open Angle Glaucoma and Ocular Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 64 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing latanoprost in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Latanoprost · Glaucoma, Open-Angle.

Enrollment
3rd of 39
528 · median 117
Started
2005
with 3 others
Phase 3
12 of 40
none open now
Registered
6th of 40
by date
Lead sponsor
9 of 40
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 40 studies testing latanoprost in Glaucoma, Open-Angle, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2005, is one of 12 in phase 3, and was the 6th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 40 studies testing latanoprost in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About latanoprost

Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing latanoprost in Glaucoma, Open-Angle as a file.
02

Study summary

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.
  • History of (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
528 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The mean IOP measurements obtained in the study eye at each time point.

07

Study locations

64 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35216, United States
  • Pfizer Investigational Site
    Flagstaff, Arizona 86001, United States
  • Pfizer Investigational Site
    Artesia, California 90701, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    Newport Beach, California 92663, United States
  • Pfizer Investigational Site
    Sacramento, California 95815, United States
  • Pfizer Investigational Site
    San Francisco, California 94105, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80907, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32605, United States
  • Pfizer Investigational Site
    Lecanto, Florida 34461, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Panama City, Florida 32405, United States
  • Pfizer Investigational Site
    Idaho Falls, Idaho 83404, United States
  • Pfizer Investigational Site
    Bourbonnais, Illinois 60914, United States
  • Pfizer Investigational Site
    Calumet City, Illinois 60409, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60611, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60617, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47713, United States
  • Pfizer Investigational Site
    Madison, Indiana 47250, United States
  • Pfizer Investigational Site
    New Albany, Indiana 47150, United States
  • Pfizer Investigational Site
    Newburgh, Indiana 47630, United States
  • Pfizer Investigational Site
    Iowa City, Iowa 52245, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67208, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Bangor, Maine 04401, United States
  • Pfizer Investigational Site
    Reading, Massachusetts 01867, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48105, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48201-1423, United States
  • Pfizer Investigational Site
    Stillwater, Minnesota 55082, United States
  • Pfizer Investigational Site
    Creve Coeur, Missouri 63141-6846, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64114, United States
  • Pfizer Investigational Site
    Warrensburg, Missouri 64093, United States
  • Pfizer Investigational Site
    Washington, Missouri 63090, United States
  • Pfizer Investigational Site
    Piscataway, New Jersey 08854-4143, United States
  • Pfizer Investigational Site
    Princeton, New Jersey 08540-3211, United States
  • Pfizer Investigational Site
    Brooklyn, New York 11215, United States
  • Pfizer Investigational Site
    New York, New York 10032-3701, United States
  • Pfizer Investigational Site
    Rochester, New York 14618, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27704-2122, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Greensboro, North Carolina 27408-7022, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27101, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44115-3176, United States
  • Pfizer Investigational Site
    Roseburg, Oregon 97470, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19148, United States
  • Pfizer Investigational Site
    Reading, Pennsylvania 19606, United States
  • Pfizer Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29403, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29414, United States
  • Pfizer Investigational Site
    Maryville, Tennessee 37803, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Austin, Texas 78746, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231-5185, United States
  • Pfizer Investigational Site
    El Paso, Texas 79902, United States
  • Pfizer Investigational Site
    El Paso, Texas 79904, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76102-4427, United States
  • Pfizer Investigational Site
    Houston, Texas 77025-1635, United States
  • Pfizer Investigational Site
    Houston, Texas 77055, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78205, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78209, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78240, United States
  • Pfizer Investigational Site
    Fredericksburg, Virginia 22405, United States
  • Pfizer Investigational Site
    Seattle, Washington 98133, United States
08

References and documents

Publications

  • Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS; United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010 Feb;128(2):165-72. doi: 10.1001/archophthalmol.2009.384. PubMed 20142538 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2006
First posted
Jan 16, 2006
Start
Dec 2005
CompletionActual
Jun 2007
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00277498
Responsible party
Sponsor
First posted
Jan 16, 2006
Start date
Dec 2005
Completion
Jun 2007
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xalacom · Latanoprost · Timolol

Start the discussion